OJCD  Vol.3 No.3 , September 2013
Acute non-renal adverse events after unenhanced and enhanced computed tomography and magnetic resonance imaging
Abstract: Aim: Investigating the incidence of non-renal acute adverse events (AAEs) in patients undergoing unenhanced or enhanced computed tomography (CT) or magnetic resonance (MR) (four groups) using the ac- tive interview-method. Methods: The imaging procedure followed the standards of the department. Furthermore, the iodine-based (nonionic monomer) and gadolinium-based (cyclic) contrast agent was the same as used for all other examinations in the department. All patients were interviewed for 72 hours after the MR or CT examination regarding occurrence of AAEs using a structured questionnaire. Results: A total of 1358 patients (259 with enhanced MR, 434 with unenhanced MR, 450 with enhanced CT and 215 with unenhanced CT) were enrolled. AAEs were significantly higher (P < 0.05) in the contrast enhanced MR [48 (18.5%)] and CT [35 (7.7%)] groups compared to unenhanced MR [39 (9.0%)] and CT [5 (2.3%)] groups. Dizziness was significantly [19 (7.3%), (P < 0.05)] more frequent in the enhanced MR. The same AAEs were reported in both contrast groups and control groups. Conclusion: AAEs which are mainly considered to be caused by the contrast medium are also experienced by patients undergoing CT or MR without contrast. Enhanced MR is correlated with more reactions than unenhanced MR and enhanced CT. Dizziness was reported more frequently after MR than CT, both with and without contrast; more patients were CNS examined with MR and with CT.
Cite this paper: Azzouz, M. , Rømsing, J. and S. Thomsen, H. (2013) Acute non-renal adverse events after unenhanced and enhanced computed tomography and magnetic resonance imaging. Open Journal of Clinical Diagnostics, 3, 85-93. doi: 10.4236/ojcd.2013.33016.

[1]   Thomsen, H.S. and Webb, J. (2012) The Lalli and Weber effects and the incidence of acute non-renal adverse reactions to contrast media. Acta Radiologica, 53, 953-954. doi:10.1258/ar.2012.12a006

[2]   Lalli, A.F. (1980) Contrast media reactions: Data analysis and hypothesis. Radiology, 134, 1-12.

[3]   Weber, J.C.P. (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford, K.D. and Velo, G.D., Eds., Side-effects of anti-inflammatory drugs, advances in inflammation research. Raven Press, New York, 1-7.

[4]   Schild, H.H., Kuhl, C.K., Hübner-Steiner, U., Bohm, I. and Speck, U. (2006) Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: A prospective randomized controlled trial. Radiology, 240, 56-64. doi:10.1148/radiol.2393050560

[5]   Dillman, J.R., Ellis, J.H., Cohan, R.H., Strouse, P.J. and Jan, S.C. (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR American Journal of Roentgenology, 189, 1533-1538. doi:10.2214/AJR.07.2554

[6]   Murphy, K.J., Brunberg, J.A. and Cohan, R.H. (1996) Adverse reactions to gadolinium contrast media: A review of 36 cases. AJR American Journal of Roentgenology, 167, 847-849. doi:10.2214/ajr.167.4.8819369

[7]   Knopp, M.V., Balzer, T., Esser, M., Kashanian, F.K., Paul, P. and Niendorf, H.P. (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentate dimeglumine as a magnetic resonance contrast media after 45 million administrations and 15 years of clinical use. Investigative Radiology, 41, 491-499. doi:10.1097/01.rli.0000209657.16115.42

[8]   Morcos, S.K. and Thomsen, H.S. (2001) Adverse reactions to iodinated contrast media. European Radiology, 11, 1267-1275. doi:10.1007/s003300000778

[9]   Thomsen, H.S. (1997) Frequency of acute adverse events to a non-ionic low-osmolar contrast medium: The effect of verbal interview. Pharmacology & Toxicology, 80, 108-110. doi:10.1111/j.1600-0773.1997.tb00292.x

[10]   Niendorf, H.P., Dinger, J.C., Haustein, J., Cornelius, I., Alhassan, A. and Clauss, W. (1991) Tolerance data of Gd-DTPA: A review. European Journal of Radiology, 13, 15-20. doi:10.1016/0720-048X(91)90049-2

[11]   Nelson, K.L., Gifford, L.M., Lauber-Huber, C., Gross, C.A. and Lasser, T.A. (1995) Clinical safety of gadopentetate dimeglumine. Radiology, 196, 439-443.

[12]   Hunt, C.H., Hartman, R.P. and Hesley, G.K. (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: Retrospective review of 456,930 doses. AJR American Journal of Roentgenology, 193, 1124-1127. doi:10.2214/AJR.09.2520

[13]   Goldstein, H.A., Kashanian, F.K., Blumettei, R.F., Holyoak, W.L., Hugo, F.P. and Blumenfield, D.M. (1990) Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology, 174, 17-23.

[14]   Shellock, F.G., Morisoli, S.M. and Ziarati, M. (1994) Measurement of acoustic noise during MR imaging: Evaluation of six “Worst-Case” pulse sequences. Radiology, 191, 91-93.

[15]   Forsting, M. and Palkowitsch, P. (2010) Prevalence of Acute adverse events to gadobutrol—A highly concentrated macrocyclic gadolinium chelate: Review of 14,299 patients from observational trials. European Journal of Radiology, 74, e186-e192. doi:10.1016/j.ejrad.2009.06.005

[16]   Bruder, O., Schneider, S., Nothnagel, D., Pilz, G., Lombardi, M., Sinha, A., Wagner, A., Dill, T., Frank, H, van Rossum, A., Schwitter, J., Nagel, E., Senges, J., Sabin, G., Sechtem, U. and Mahrholdt, H. (2011) Acute adverse events to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the Euro CMR Registry. JACC Cardiovasc Imaging, 4, 1171-1176. doi:10.1016/j.jcmg.2011.06.019

[17]   Abujudeh, H.H., Kosaraju, V.K. and Kaewlai, R. (2010) Acute adverse events to gadopentetate dimeglumine and gadobenate dimeglumine: Experience with 32,659 injections. AJR American Journal of Roentgenology, 194, 430-434. doi:10.2214/AJR.09.3099

[18]   Li, A., Wong, C.S., Wong, M.K., Lee, C.M. and Au Yeung, M.C. (2006) Acute adverse events to magnetic resonance contrast media: Gadolinium chelates. British Journal of Radiology, 79, 368-371. doi:10.1259/bjr/88469693

[19]   Herborn, C.U., Honold, E., Wolf, M., Kemper, J., Kinner, S., Adam, G. and Barkhausen, J. (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Investigative Radiology, 42, 58-62. doi:10.1097/01.rli.0000248893.01067.e5

[20]   Ishiguchi, T. and Takahashi, S. (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: Results of a post-marketing surveillance study in Japan. Drugs R D, 10, 133-145. doi:10.2165/11539140-000000000-00000

[21]   Dooley, M. and Jarvis, B. (2000) Iomeprol: A review of its use as a contrast medium. Drugs, 59, 1169-1186. doi:10.2165/00003495-200059050-00013

[22]   Davenport, M.S., Dillman, J.R., Cohan, R.H., Hussain, H.K., Khalatbari, S., McHugh, J.B. and Ellis, J.H. (2013) Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology, 266, 773-782. doi:10.1148/radiol.12120253

[23]   Brugières, P., Gaston, A., Degryse, H.R., Parizel, P.M., de Schepper, A.M., Berry, I., Manelfe, C., Le Bras, F., Marsault, C., Wichmann, W. and Valavanis, A. (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology, 36, 27-30. doi:10.1007/BF00599189